Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$7.9 million.

  • Allogene Therapeutics' Net Cash Flow rose 87.84% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.4 million, marking a year-over-year increase of 25.45%. This contributed to the annual value of -$7.9 million for FY2024, which is 137.35% down from last year.
  • As of FY2024, Allogene Therapeutics' Net Cash Flow stood at -$7.9 million, which was down 137.35% from $21.3 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Net Cash Flow peaked at $21.3 million during FY2023, and registered a low of -$111.4 million during FY2022.
  • Moreover, its 3-year median value for Net Cash Flow was -$7.9 million (2024), whereas its average is -$32.7 million.
  • In the last 5 years, Allogene Therapeutics' Net Cash Flow tumbled by 1,111.77% in 2022 and then surged by 119.07% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Net Cash Flow (Yearly) stood at $13.4 million in 2020, then plummeted by 168.74% to -$9.2 million in 2021, then tumbled by 1,111.77% to -$111.4 million in 2022, then skyrocketed by 119.07% to $21.3 million in 2023, then tumbled by 137.35% to -$7.9 million in 2024.